Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Takeda Pharmaceutical Co. (TAK) had Consolidated Net Income/Loss of $713.51M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$7.69B |
|
$713.14M |
|
$2.56B |
|
$5.12B |
|
$6.42B |
|
$1.27B |
|
$-243.80M |
|
$1.03B |
|
$1.03B |
|
$713.51M |
|
$713.51M |
|
|
Consolidated Net Income/Loss |
$713.51M |
$713.51M |
|
$1.27B |
|
$2.30B |
|
3.16B |
|
3.16B |
|
$0.23 |
|
$0.22 |
|
| Balance Sheet Financials | |
$19.85B |
|
$13.50B |
|
$78.83B |
|
$98.68B |
|
$17.42B |
|
$27.85B |
|
$33.64B |
|
$51.06B |
|
$47.62B |
|
$-10.83B |
|
$47.62B |
|
3.16B |
|
| Cash Flow Statement Financials | |
$804.02M |
|
$-552.53M |
|
$-1.14B |
|
$3.75B |
|
$2.90B |
|
$-844.65M |
|
$114.60M |
|
$-945.83M |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.14 |
|
-- |
|
-- |
|
0.37 |
|
0.65 |
|
66.66% |
|
16.51% |
|
16.51% |
|
-- |
|
13.34% |
|
9.28% |
|
$471.92M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.28 |
|
1.28 |
|
70.54 |
|
1.50% |
|
-6.59% |
|
0.72% |
|
0.95% |
|
$15.07 |
|
$0.15 |
|
$0.25 |
|